Insulin-like growth factor binding protein 6 (IGFBP6)

Insulin-like growth factor binding protein 6 (IGFBP-6) is a specialized member of the IGFBP family characterized by its uniquely high affinity for IGF-II, which is 10 to 100 times greater than its affinity for IGF-I. Its primary physiological role is to act as a natural antagonist of IGF-II by sequestering the growth factor and preventing the activation of the IGF-I receptor signaling pathway. Beyond this inhibitory role, IGFBP-6 is known to perform IGF-independent functions, such as regulating the chemotaxis of T-cells and dendritic cells and inducing apoptosis in various cell types through nuclear translocation. In clinical contexts, IGFBP-6 is often viewed as a tumor suppressor, particularly in IGF-II-dependent malignancies like neuroblastoma and rhabdomyosarcoma, where its downregulation is associated with increased tumor progression. Conversely, elevated levels of IGFBP-6 have been implicated in the pathogenesis of fibrotic diseases and certain specialized cancers, highlighting its complex role in tissue remodeling. Although no drugs targeting or utilizing IGFBP-6 are currently FDA-approved, it is an active area of research for the development of anti-tumor therapies and as a diagnostic biomarker for fibrotic and oncological conditions.

Other names

IGF-binding protein 6IBP-6IGFBP-6

IGFBP6 primarily acts by binding to insulin-like growth factor II (IGF-II) with high affinity, thereby preventing IGF-II from interacting with its cognate receptor (IGF-1R) and inhibiting downstream proliferative signaling. It also exerts IGF-independent effects by interacting with intracellular proteins and translocating to the nucleus to modulate gene expression related to apoptosis and migration.